Inhibitory effect of (−)-epigallocatechin-3-gallate and bleomycin on human pancreatic cancer MiaPaca-2 cell growth

Bimonte, Sabrina; Leongito, Maddalena; Barbieri, Antônio; Vecchio, Vitale Del; Barbieri, Massimiliano; Albino, Vittorio; Piccirillo, Mauro; Amore, Alfonso; Giacomo, Raimondo Di; Nasto, Aurelio; Granata, Vincenza; Petrillo, Antonella; Arra, Claudio; Izzo, Francesco

doi:10.1186/s13027-015-0016-y

Cited by 48 publications

(27 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar synergistic effects were observed with oxaliplatin, a cisplatin derivative (Hu et al, 2015). Cooperative effect was observed when the anti-cancer, DNA binding compound bleomycin was used in conjunction with EGCG, showing a potentiated anti-proliferative effect in pancreatic cancer cells (Bimonte et al, 2015). Additionally, interaction of EGCG in single-strand DNA chains showed increased nuclease activity in whole blood and isolated lymphocytes cells (Yuquan, Takeshita, & Morimoto, 2001).…”

Section: Introductionmentioning

confidence: 61%

Computational DNA binding studies of (–)-epigallocatechin-3-gallate

Galindo‐Murillo

Cheatham

2017

Journal of Biomolecular Structure and Dynamics

View full text Add to dashboard Cite

The catechin family of molecules that are present in the leaves of green tea has been under investigation since the antioxidant and anti-inflammatory properties of tea were discovered. Among multiple proposed therapeutic targets of these molecules, the direct interaction with nucleic acids has been proposed and experimentally observed but without clear knowledge about the potential binding modes between these ligands and DNA. One of these catechin structures, (-)-epigallocatechin gallate (EGCG), has three aromatic rings that could interact with double-stranded DNA via terminal base-pair stacking, intercalation, or through groove binding. Using enhanced sampling techniques and molecular dynamics simulations, we have found a stable complex between the EGCG ligand and DNA through intercalation of the trihydroxybenzoate aromatic ring and an ApC step. Moreover, we have calculated the absorption spectra of four possible binding modes and compared these to absorption profiles reported in the literature, and explored the possible DNA sequence preference for the EGCG ligand to bind. Our results suggest that an intercalative mode of interaction through the major groove is possible between the EGCG ligands and DNA with apparently very little DNA sequence selectivity.

show abstract

Section: Introductionmentioning

confidence: 61%

Computational DNA binding studies of (–)-epigallocatechin-3-gallate

Galindo‐Murillo

Cheatham

2017

Journal of Biomolecular Structure and Dynamics

View full text Add to dashboard Cite

show abstract

“…Cells were washed and suspended in 0.5 ml of phosphate-buffered saline, fluorescein isothiocyanate-dextran, annexin V and propidium iodide (PI). The in vitro assay was performed as described by Bimonte et al (15).…”

Section: Methodsmentioning

confidence: 99%

“…Cell-cycle analysis. The cells were seeded at 3×10 5 cells per well into 6-well plates and incubated overnight at 37˚C in a CO 2 incubator (15). The cells were then washed with phosphatebuffered saline and treated with medium as control or with EGCG (40 μM), tapentadol (20 mg/ml), or their combinations (40 μM EGCG plus 20 mg/ml tapentadol), and incubated for 24 and 48 h. Analysis was performed as described by Bimonte et al (15).…”

Section: Methodsmentioning

confidence: 99%

“…Several studies have shed light on new possible therapeutic approaches for breast cancer management, based on the combination of natural compounds with conventional drugs (6,7). (-)-Epigallocatechin gallate (EGCG), the main catechin of green tea (8)(9)(10)(11), is able to inhibit tumor progression in several types of cancer (12)(13)(14)(15), such as breast cancer (10,16,17), due to its antioxidant and anti-inflammatory properties (18,19).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Shining a Light on the Effects of the Combination of (–)-Epigallocatechin-3-gallate and Tapentadol on the Growth of Human Triple-negative Breast Cancer Cells

Bimonte

Cascella

Barbieri

et al. 2019

In Vivo

Self Cite

View full text Add to dashboard Cite

Background/Aim: Breast cancer is characterized by a high rate of mortality and is considered one of the deadliest types of cancer. It is of note that (-)epigallocatechin-3-gallate (EGCG), the principal catechin of green tea, is able to hinder the growth of MDA-MB-231 breast cancer cells by influencing different signaling pathways, including apoptosis. Furthermore, EGCG is also used in the treatment of bone cancer pain. Tapentadol, an opioid drug acting at the level of noradrenaline (norepinephrine) reuptake inhibition and μ-opioid receptor, is able to modulate bone cancer pain and influence cancer cell viability by regulating apoptosis. Materials and Methods: In vitro assays were performed on triple-negative MDA-MB-231 cells treated with tapentadol (1,5,10,20, 40 and 80 μg/ml) and EGCG (1,10,20, 40, 80, 160 μmol/l), alone and in combination. The effects of EGCG and TAP on viability were determined by woundhealing and MTT assays, while cell migration was assessed by transwell migration. Results: Cell proliferation, viability and apoptosis of MDA-MB-231 cells were impaired by the combination of EGCG and tapentadol. Specifically, our data show that EGCG and TAP reduced the proliferation of MDA-MB-231 cells by impairing cell-cycle progression (p<0.05). These findings suggest that the combination of these substances may represent a new strategy for the treatment of patients suffering from triple-negative breast cancer.

show abstract

“…Promising results obtained by in vitro and in vivo studies on the use of EGCG as valuable therapeutic options for neurodegenerative disorders and cancer treatments, encourage its commitment to translation into clinical practice [39, 40].

The bioavailability of EGCG in the brain: a discrepancy between animals and humans-based studies

Despite these encouraging results, there is still a translational gap between in vitro, in vivo and clinical studies with EGCG in neurodegenetative disease treatment.

…”

Section: Introductionmentioning

confidence: 99%

The efficacy of Epigallocatechin-3-gallate (green tea) in the treatment of Alzheimer’s disease: an overview of pre-clinical studies and translational perspectives in clinical practice

Cascella

Bimonte

Muzio³

et al. 2017

Infect Agents Cancer

Self Cite

129

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a neurodegenerative disorder and the most common form of dementia characterized by cognitive and memory impairment. One of the mechanism involved in the pathogenesis of AD, is the oxidative stress being involved in AD‘s development and progression. In addition, several studies proved that chronic viral infections, mainly induced by Human herpesvirus 1 (HHV-1), Cytomegalovirus (CMV), Human herpesvirus 2 (HHV-2), and Hepatitis C virus (HCV) could be responsible for AD’s neuropathology. Despite the large amount of data regarding the pathogenesis of Alzheimer’s disease (AD), a very limited number of therapeutic drugs and/or pharmacological approaches, have been developed so far. It is important to underline that, in recent years, natural compounds, due their antioxidants and anti-inflammatory properties have been largely studied and identified as promising agents for the prevention and treatment of neurodegenerative diseases, including AD. The ester of epigallocatechin and gallic acid, (−)-Epigallocatechin-3-Gallate (EGCG), is the main and most significantly bioactive polyphenol found in solid green tea extract. Several studies showed that this compound has important anti-inflammatory and antiatherogenic properties as well as protective effects against neuronal damage and brain edema. To date, many studies regarding the potential effects of EGCG in AD’s treatment have been reported in literature. The purpose of this review is to summarize the in vitro and in vivo pre-clinical studies on the use of EGCG in the prevention and the treatment of AD as well as to offer new insights for translational perspectives into clinical practice.

show abstract

Inhibitory effect of (−)-epigallocatechin-3-gallate and bleomycin on human pancreatic cancer MiaPaca-2 cell growth

Cited by 48 publications

References 38 publications

Computational DNA binding studies of (–)-epigallocatechin-3-gallate

Computational DNA binding studies of (–)-epigallocatechin-3-gallate

Shining a Light on the Effects of the Combination of (–)-Epigallocatechin-3-gallate and Tapentadol on the Growth of Human Triple-negative Breast Cancer Cells

The efficacy of Epigallocatechin-3-gallate (green tea) in the treatment of Alzheimer’s disease: an overview of pre-clinical studies and translational perspectives in clinical practice

Contact Info

Product

Resources

About